Apotex

Toronto, Canada Founded: 1974 • Age: 52 yrs Listed Acquired By SK Capital
Generic pharmaceutical formulations are manufactured and exported by Apotex globally.

About Apotex

Apotex is a publicly listed company based in Toronto (Canada) founded in 1974, and was acquired by SK Capital in September 2022. Generic pharmaceutical formulations are manufactured and exported by Apotex globally. The company has 13 employees. Apotex has completed 2 acquisitions, including Aveva and Searchlight Pharma. Its chief executive, as recorded, is Allan Oberman. Its website apotex.com draws about 60 thousand monthly visits. Its Indian entity Apotex Research Private Limited reported revenue of ₹727 Cr. Its focus areas include Traditional Pharmaceuticals, Generics and Diversified.

Company details

Apotex was founded in 1974 in Toronto, Canada, within the pharmaceutical sector. Generic formulations are produced by the company, with operations including research and development on both generic and innovative drugs. Products are distributed to every pharmacy in Canada and exported to various countries worldwide. Ferriprox has been approved for managing iron overload in patients with Thalassemia.

  • Headquarters Toronto, Canada
  • Employees 13
  • Stage Acquired
  • Sectors
    Healthcare
  • Website category Health · Pharmacy
  • Phone
    •••• ••••
  • Website apotex.com
  • Social LinkedIn Facebook
  • Acquired by SK Capital (Sep 2022)
  • Legal Name Apotex Health Corp.
Key Metrics
  • Indian entity revenue
    ₹727 Cr

    FY 2025 · +22% YoY

  • Indian entity net profit
    ₹76.62 Cr

    FY 2025 · 11% margin

  • Indian entity EBITDA
    ₹149 Cr

    FY 2025 · 21% margin

  • Investors
  • Employee Count
    13
  • Investments & Acquisitions
    Aveva

    & 1 more

  • Acquired by
    SK Capital

    (Sep 2022)

Investors in Apotex

Apotex has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include SK Capital.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
A global private investment firm focused on specialty sectors.
skcapitalpartners.comNew York, United States
Premium access

Investor details for Apotex

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Apotex Research Private Limited (Apotex)

Apotex Research Private Limited is the primary company behind Apotex. The board of Apotex Research Private Limited currently have 4 directors; the longest-serving is Goutam Vilas Pujari, appointed in 2018. 15 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Goutam Vilas Pujari
DIN 02891339
Director01 Dec 20187 yrs 11 moApotex Research Private Limited
Brian George Mcclelland
DIN 06568789
Director15 Sep 20233 yrs 2 moApotex Research Private Limited
Rajesh Salwan
DIN 07669286
Additional Director18 Mar 20251 yr 8 moApotex Research Private Limited
Uta Kellermann Renton
DIN 10993254
Additional Director18 Mar 20251 yr 8 moApotex Research Private Limited

People of Apotex

218 people are tracked at Apotex (102 in leadership, 116 in team); the tracked headcount is 13.

NameRoleGroup
Allan Oberman
CEOLeadership
Aditya Jaiswal
Director, Strategy & Analytics, Global Corporate DevelopmentLeadership
Saad Khanzada
Senior Director Of FinanceLeadership
Joe Carrier
Senior Director Forecasting And Demand PlanningLeadership
Melissa Bernard
Associate Director, Site EngineeringLeadership
Kevin Mach
Associate Director, Capital Engineering - Leasehold Improvements, Laboratory, Research & DevelopmentLeadership
Amit B.
Deputy General Manager - Global Intellectual PropertyLeadership
Donald D'Anna
Vice President - Tax & TreasuryLeadership
Art Tramonte
Vice President, Commercial Rest Of WorldLeadership
Daniel Johnson
Associate Director, Product Management & Commercial OperationsLeadership
Rachel Floyd
Director, Senior Legal CounselLeadership
Carlo Carinci
Global Director, Platform & Cloud ServicesLeadership
Jim Wheat
Vice President Product Supply SignetLeadership
Francesco Tallarico
Chief Legal OfficerLeadership
Hector Rodriguez
Latam Finance DirectorLeadership
Olga Kalinina
Director, Global Intellectual Property And Legal AffairsLeadership
Lorena F.
Chief Information OfficerLeadership
Miroslav Preradovic
Director, IT Services ManagementLeadership
Sadia Khan
Director, Corporate FinanceLeadership
Sagiv Levi
Vice President, Head Of Global Transformation And OPEXLeadership

198 more people are available in the full profile.

Premium access

Complete people profiles for Apotex

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Apotex

Apotex is a publicly listed company on the TSX with ticker symbol APTX in Canada, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date10 Jun 2026
  • Listed onTSX: APTX
  • Listed entityApotex Health Corp.
  • Exchange sectorHealth technology
  • ISINCA03772D1015
  • Share price30.89 CAD (+0.32% on the day) · 2026-10-13
  • Market capitalisation7,035,484,825.80 CAD
  • Volume (last session)275,119

Financials of Apotex

Figures of Apotex Research Private Limited, the primary company behind Apotex, for FY 2025. Revenue was ₹727 Cr (+22% year on year). Net profit was ₹76.62 Cr (11% margin). EBITDA was ₹149 Cr (21% margin). Revenue has grown at a compounded annual rate of +10% over three years and +931% over five years.

  • ₹727 CrRevenue · FY 2025 · +22% YoY
  • ₹76.62 CrNet profit · 11% margin
  • ₹149 CrEBITDA · 21% margin
  • ₹292 CrPaid-up capital
  • 1,236Employees (provident fund records)
  • +10%Revenue CAGR, 3 years
  • +931%Revenue CAGR, 5 years

Balance sheet, profit and loss, cash flow and ratios of Apotex Research Private Limited are on its company page.

Premium access

Detailed financial statements for Apotex

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Apotex

Apotex has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Aveva and Searchlight Pharma.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Specialty pharmaceuticals are acquired, developed, and commercialized by the company.
searchlightpharma.comMontreal, Canada2015Apr 2024••••
Drugs for multiple therapeutic areas are manufactured by Aveva.
avevadds.comMiramar, United States2003Jun 2012••••
Premium access

Complete acquisition details for Apotex

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Apotex

5 dated milestones of Apotex across 52 years, from founding to its latest funding, stage changes and deals.

  1. Founded Apotex is founded.
  2. Acquisition Acquires Aveva.
  3. Exit Acquired by SK Capital.
  4. Acquisition Acquires Searchlight Pharma.
  5. IPO Lists on the stock exchange (IPO).

Web traffic of Apotex

The website of Apotex (apotex.com) receives about 60.3K visits a month and ranks #457,120 among all websites worldwide, #847 in Pharmacy.

  • Monthly visits
    60.3K

    ▼ 17% vs previous month

  • Unique visitors
    30.5K

    per month

  • Global rank
    #457,120

    among all websites

  • Category rank
    #847

    Health · Pharmacy

Similar websites

Websites whose visitors overlap most with Apotex. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
pfizer.ca
100%
#1,068,167View details
astrazeneca.ca
astrazeneca.ca
84%
#973,246–
ycdscc.com
81%
#1,322,015View details
carerx.ca
80%
46.7K#724,974View details
biovail.com
79%
View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 27 similar websites and full traffic analytics for Apotex

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 27 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Apotex

Premium access

Complete news archive for Apotex

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Apotex

Apotex was founded in 1974.

Apotex is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.

Allan Oberman is the CEO of Apotex, as recorded in our data.

Apotex has 13 employees.

The primary company behind Apotex, Apotex Research Private Limited, reported revenue of ₹727 Cr for FY 2025, up 22% year on year.

Apotex was founded in 1974 in Toronto, Canada, within the pharmaceutical sector. Generic formulations are produced by the company, with operations including research and development on both generic and innovative drugs. Products are distributed to every pharmacy in Canada and exported to various countries worldwide. Ferriprox has been approved for managing iron overload in patients with Thalassemia.

Yes, Apotex is publicly traded on TSX under the ticker symbol APTX.

Apotex has made 2 acquisitions, including Aveva, and Searchlight Pharma.

Apotex has 1 investor. Key investors include SK Capital.

Apotex operates through Apotex Research Private Limited.

Yes. Apotex was acquired by SK Capital in September 2022.

The legal entities of Apotex currently have 5 directors, including Brian George Mcclelland, Rajesh Salwan, Goutam Vilas Pujari and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available